$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
Efficacy of transauricular vagus nerve stimulation for the treatment of chemotherapy-induced painful peripheral neuropathy: a randomized controlled exploratory study
Neurol Sci
2024 May;45(5):2289-2300. doi: 10.1007/s10072-023-07229-2. Epub 2023 Dec 8.
Author
Yifan Yang , Ran Zhang , Zhifang Zhong , Jun Li , Yi Feng
Affiliations
1Department of Pain Medicine, Peking University People’s Hospital, Beijing, People’s Republic of China.
2Department of Anesthesiology, Peking University People’s Hospital, Beijing, People’s Republic of China.
3Department of Pain Medicine, Peking University People’s Hospital, Beijing, People’s Republic of China. clivia.li@163.com.
4Department of Pain Medicine, Peking University People’s Hospital, Beijing, People’s Republic of China. fengyi@pkuph.edu.cn.
Contributed equally.
Abstract
Background
Chemotherapy-induced painful peripheral neuropathy (CIPN) is a common adverse event in cancer patients, and there is still a lack of effective treatment. Transauricular vagal nerve stimulation (taVNS) is a minimally invasive treatment, but there are few reports regarding its efficacy for CIPN.
Objective
To investigate the efficacy and possible mechanism of taVNS in patients with CIPN.
Methods
Twenty-seven patients with CIPN were randomly divided into a taVNS group (n = 14) and a sham stimulation (SS) group (n = 13). A numerical rating scale (NRS) for pain, NCICTCAE 4.0 (neurotoxicity classification), quantitative sensory test (QST), Short-Form-Health Survey-12 (SF-12), and Athens Insomnia Scale (AIS) were administered before the intervention (D-10) and on the day after the intervention (D0), and the inflammatory cytokines in plasma were also measured. The NRS, NCI-CTCAE 4.0, SF-12, and AIS were administered again at D30 and D90.
Results
Compared with the SS group, the NRS and AIS in the taVNS group were significantly lower at D0. The impact lasted until D30. There were no statistically significant differences in the NRS and AIS between the 2 groups at D90. On D30, the mental component score of the SF-12 was significantly higher in the taVNS group than in the SS group. No adverse events were found. There was no significant difference in QST and plasma inflammatory cytokines between the 2 groups.
Conclusion
taVNS can relieve chemotherapy-induced neuropathic pain in the short term, can improve sleep status and quality of life, and is expected to become a novel clinical treatment method for CIPN.
Keywords:
Chemotherapy-induced peripheral neuropathy (CIPN); Transauricular vagus nerve stimulation (taVNS); Vagus nerve stimulation (VNS).
© 2023. Fondazione Società Italiana di Neurologia.